Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma

Numakura,Kazuyuki; Tsuchiya,Norihiko; Akihama,Susumu; Inoue,Takamitsu; Narita,Shintaro; Huang,Mingguo; Satoh,Shigeru; Habuchi,Tomonori

doi:10.3892/ol.2014.2118

July-2014 Volume 8 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2014 Volume 8 Issue 1

Full Size Image

Article

Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma

Authors:
- Kazuyuki Numakura
- Norihiko Tsuchiya
- Susumu Akihama
- Takamitsu Inoue
- Shintaro Narita
- Mingguo Huang
- Shigeru Satoh
- Tomonori Habuchi
View Affiliations / Copyright

Affiliations: Department of Urology, Akita University Graduate School of Medicine, Akita 010‑8543, Japan
Pages: 464-466
|
Published online on: May 7, 2014

https://doi.org/10.3892/ol.2014.2118
Expand metrics +

Abstract

This study presents a case of metastatic sarcomatoid renal cell carcinoma (RCC) treated with systemic chemotherapy followed by mammalian target of rapamycin inhibitor maintenance therapy. A 63‑year‑old male presented with lumbago, and lumbar vertebral tumors were detected by magnetic resonance imaging. Subsequent computed tomography (CT) revealed a right renal tumor and CT‑guided biopsy of the right renal and left sacroiliac tumors determined pure sarcomatoid carcinoma without a clear cell component. Two cycles of combination chemotherapy comprising of gemcitabine (1,500 mg/m2 on day one) and doxorubicin (50 mg/m2 on day one) resulted in a 20% reduction in the longest diameter of the right renal tumor. However, due to grade 3 neutropenia, the chemotherapy was discontinued and temsirolimus (25 mg once weekly), which binds to the cytoplasmic protein, FKBP-12, and inhibits mTOR, was administered. Stable disease was maintained for 19 months with temsirolimus and no major adverse events, with the exception of grade 2 nausea, were observed. The patient succumbed to their disease at 30 months following the initiation of treatment. These results suggested that systemic chemotherapy followed by temsirolimus maintenance is a feasible treatment option for patients with metastatic sarcomatoid RCC.

View Figures

View References

1	Sun M, Thuret R, Abdollah F, et al: Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 59:135–141. 2011.
2	Basso M, Cassano A and Barone C: A survey of therapy for advanced renal cell carcinoma. Urol Oncol. 24:121–133. 2010.
3	de Peralta-Venturina M, Moch H, Amin M, et al: Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 25:275–284. 2001.
4	Haas NB, Lin X, Manola J, et al: A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 29:761–767. 2012.
5	Molina AM, Tickoo SK, Ishill N, et al: Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol. 34:454–459. 2011.
6	Tannir NM, Plimack E, Ng C, et al: A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 62:1013–1019. 2012.
7	Nanus DM, Garino A, Milowsky MI, et al: Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 101:1545–1551. 2004.
8	Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007.
9	Areses MC, Herranz UA, Ferrán BB, et al: Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases. Med Oncol. 29:795–798. 2012.
10	Staehler M, Haseke N, Roosen A, et al: Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res. 15:287–291. 2010.
11	Michaelson DF, McDermott MB, Atkins DC, et al: Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. J Clin Oncol. 28(suppl 15): e150762010.
12	Corradetti MN and Guan KL: Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene. 25:6347–6360. 2006.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles